Effect of School Integrated Pest Management or Classroom Air Filter Purifiers on Asthma Symptoms in Students With Active Asthma: A Randomized Clinical Trial.
Journal
JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160
Informations de publication
Date de publication:
07 09 2021
07 09 2021
Historique:
entrez:
21
9
2021
pubmed:
22
9
2021
medline:
30
9
2021
Statut:
ppublish
Résumé
School and classroom allergens and particles are associated with asthma morbidity, but the benefit of environmental remediation is not known. To determine whether use of a school-wide integrated pest management (IPM) program or high-efficiency particulate air (HEPA) filter purifiers in the classrooms improve asthma symptoms in students with active asthma. Factorial randomized clinical trial of a school-wide IPM program and HEPA filter purifiers in the classrooms was conducted from 2015 to 2020 (School Inner-City Asthma Intervention Study). There were 236 students with active asthma attending 41 participating urban elementary schools located in the Northeastern US who were randomized to IPM by school and HEPA filter purifiers by classroom. The date of final follow-up was June 20, 2020. The school-wide IPM program consisted of application of rodenticide, sealing entry points, trap placement, targeted cleaning, and brief educational handouts for school staff. Infestation was assessed every 3 months, with additional treatments as needed. Control schools received no IPM, cleaning, or education. Classroom portable HEPA filter purifiers were deployed and the filters were changed every 3 months. Control classrooms received sham HEPA filters that looked and sounded like active HEPA filter purifiers. Randomization was done independently (split-plot design), with matching by the number of enrolled students to ensure a nearly exact 1:1 student ratio for each intervention with 118 students randomized to each group. Participants, investigators, and those assessing outcomes were blinded to the interventions. The primary outcome was the number of symptom-days with asthma during a 2-week period. Symptom-days were assessed every 2 months during the 10 months after randomization. Among the 236 students who were randomized (mean age, 8.1 [SD, 2.0] years; 113 [48%] female), all completed the trial. At baseline, the 2-week mean was 2.2 (SD, 3.9) symptom-days with asthma and 98% of the classrooms had detectable levels of mouse allergen. The results were pooled because there was no statistically significant difference between the 2 interventions (P = .18 for interaction). During a 2-week period, the mean was 1.5 symptom-days with asthma after use of the school-wide IPM program vs 1.9 symptom-days after no IPM across the school year (incidence rate ratio, 0.71 [95% CI, 0.38-1.33]), which was not statistically significantly different. During a 2-week period, the mean was 1.6 symptom-days with asthma after use of HEPA filter purifiers in the classrooms vs 1.8 symptom-days after use of sham HEPA filter purifiers across the school year (incidence rate ratio, 1.47 [95% CI, 0.79-2.75]), which was not statistically significantly different. There were no intervention-related adverse events. Among children with active asthma, use of a school-wide IPM program or classroom HEPA filter purifiers did not significantly reduce symptom-days with asthma. However, interpretation of the study findings may need to consider allergen levels, particle exposures, and asthma symptoms at baseline. ClinicalTrials.gov Identifier: NCT02291302.
Identifiants
pubmed: 34547084
pii: 2783822
doi: 10.1001/jama.2021.11559
pmc: PMC8424475
doi:
Substances chimiques
Allergens
0
Rodenticides
0
Banques de données
ClinicalTrials.gov
['NCT02291302']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
839-850Subventions
Organisme : NIAID NIH HHS
ID : K24 AI106822
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES005605
Pays : United States
Organisme : NIEHS NIH HHS
ID : K23 ES023700
Pays : United States
Organisme : NIEHS NIH HHS
ID : K23 ES031663
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL150341
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI110397
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI104780
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES000002
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI143962
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI106945
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES030100
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000170
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI123517
Pays : United States
Organisme : AHRQ HHS
ID : K12 HS022986
Pays : United States
Organisme : NHLBI NIH HHS
ID : L30 HL143781
Pays : United States
Investigateurs
David Kantor
(D)
Nicole Akar-Ghibril
(N)
Sigfus Gunnlaugsson
(S)
Brittany Esty
(B)
Elena Crestani
(E)
Michelle Maciag
(M)
Elizabeth Burke-Roberts
(E)
Tina Banzon
(T)
Samantha Minnicozzi
(S)
Ahmad Sedaghat
(A)
Medina Jackson
(M)
Nicole Comfort
(N)
Edie Weller
(E)
Anna Cristina Vasquez-Muniz
(AC)
Vanessa Konzelman
(V)
Giselle Garcia
(G)
Sullivan Waskosky
(S)
Anna Cristina Ramsey
(AC)
Ethan Ansel-Kelly
(E)
Vaia Bairaktaris
(V)
Darin Bell
(D)
Nicole Adler
(N)
Reid Mathews
(R)
Hana B Ruran
(HB)
Brian Volonte
(B)
John Pacheco
(J)
Aiza Zia
(A)
Julianne Saia
(J)
Alma Castillo-Hernandez
(A)
Benjamin Peterson
(B)
Jennifer Rooney
(J)
Robert Rega
(R)
Anne Bailey
(A)
Kimberly Greco
(K)
Thanaporn Ratchataswan
(T)
Stravoula Osganian
(S)
Commentaires et corrections
Type : CommentIn
Références
JAMA Pediatr. 2017 Jan 1;171(1):31-38
pubmed: 27893060
J Allergy Clin Immunol. 2012 Mar;129(3):694-701
pubmed: 22244599
Contemp Clin Trials. 2017 Sep;60:14-23
pubmed: 28619649
Indoor Air. 2021 Mar;31(2):454-466
pubmed: 32996146
Ann Allergy Asthma Immunol. 2004 Jul;93(1):36-48
pubmed: 15281470
Allergy. 2008 Nov;63(11):1512-8
pubmed: 18616677
N Engl J Med. 2000 Oct 12;343(15):1054-63
pubmed: 11027739
J Allergy Clin Immunol. 1993 Nov;92(5):636-7
pubmed: 8227853
J Allergy Clin Immunol. 2000 Dec;106(6):1075-80
pubmed: 11112889
Am J Respir Crit Care Med. 1995 Sep;152(3):1107-36
pubmed: 7663792
JAMA. 2017 Mar 14;317(10):1027-1036
pubmed: 28264080
J Allergy Clin Immunol. 2019 Feb;143(2):803-805.e10
pubmed: 30342891
J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):671-679.e4
pubmed: 27025297
J Asthma. 2021 May;58(5):616-624
pubmed: 31920176
J Allergy Clin Immunol Pract. 2017 Jan - Feb;5(1):154-159.e3
pubmed: 27641483
N Engl J Med. 1997 May 8;336(19):1356-63
pubmed: 9134876
World Allergy Organ J. 2020 Jan 08;13(1):100092
pubmed: 31934263
N Engl J Med. 2004 Sep 9;351(11):1068-80
pubmed: 15356304
N Engl J Med. 2011 Mar 17;364(11):1005-15
pubmed: 21410369
J Allergy Clin Immunol. 2017 Mar;139(3):1052-1055
pubmed: 27744028
J Allergy Clin Immunol. 2017 Aug;140(2):565-570
pubmed: 28108117